Company facts
- Headquarters
- Exton, Pennsylvania
- Most recent report
- 10-Q, filed Oct 29, 2026
- Incorporated
- Pennsylvania
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 105770
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 49
News 8 of 140
- 8-K Quarterly results Oct 29, 2026
- 8-K Significant contract Oct 26, 2026
- 8-K Quarterly results Jul 23, 2026
- 8-K Significant contract Jul 14, 2026
- 8-K Leadership change Jun 1, 2026
- 8-K/A Current report on a material event, amended May 20, 2026
- 8-K Current report on a material event May 11, 2026
- 8-K Shareholder vote results May 5, 2026
Prospectuses and Registrations 4
Proxies 8 of 32
- DEFA14A Extra proxy material Mar 12, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 12, 2026
- DEFA14A Extra proxy material Mar 21, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 21, 2025
- PRE 14A Preliminary proxy statement Mar 11, 2025
- PX14A6G Shareholder's own proxy material Mar 19, 2024
- DEFA14A Extra proxy material Mar 13, 2024
- DEF 14A Proxy statement for a shareholder vote Mar 13, 2024
Ownership 8 of 734
- SCHEDULE 13G/A Large holder reported a passive stake, amended Nov 5, 2026
- 4 Insider reported a trade Oct 2, 2026
- 4 Insider reported a trade Sep 15, 2026
- 4 Insider reported a trade Sep 10, 2026
- 4 Insider reported a trade Sep 10, 2026
- 3 Insider reported their initial holding Sep 10, 2026
- 4 Insider reported a trade Aug 12, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 6, 2026
Other 8 of 41
- SD Conflict minerals disclosure May 13, 2026
- SD Conflict minerals disclosure May 21, 2025
- ARS Annual report sent to shareholders Mar 21, 2025
- 11-K Employee stock plan report Jun 26, 2024
- 11-K Employee stock plan report Jun 26, 2024
- SD Conflict minerals disclosure May 22, 2024
- ARS Annual report sent to shareholders Mar 13, 2024
- 11-K Employee stock plan report Jun 28, 2023
What to read: Sep 2026 10-Q
SECSift found 4 of 11 sections worth reading, with 2 positive, 9 notable, and 4 negative flags.
Financial Statements (Item 1)
Section full of material events: asset sale, buyback, debt refi, litigation, restructuring, cash swing.Notable- $55.7M pre-tax gain from selling SmartDose 3.5mL system to AbbVie for $126.9M cash.
- After period end, new $750M revolver and $200M term loan extended maturities to 2031.
- January 2025 restructuring plan expanded; total expected charges now $48-50M, $26M recognized.
- Class action filed May 2025 alleging securities law violations; defendants moving to dismiss.
Management's Discussion (Item 2)
MD&A with detailed segment results, a large gain, a cyber incident, and a refinancing.PositiveNotable- Net cash from operations fell $100.3M to $403.4M in the first nine months of 2026 on higher receivables and inventory.
- Company repurchased $685.3M of stock in the first nine months of 2026, driving a $541.9M increase in financing cash outflows.
- Company completed a refinancing of senior unsecured credit facilities on October 26, 2026.
Legal Proceedings (Item 1)
Securities class action filed in May 2025, still early but material risk.NotableRisk Factors (Item 1A)
New material cyberattack disclosed in May 2026 with operational disruption.
What changed: Sep 2026 vs. Jun 2026
About 6% of WST's Sep 2026 10-Q is new information. 19 paragraphs were added, 171 changed, and 24 removed. Below are the most important lines SECSift identified.
New
- Share repurchases accelerated: $685.3M spent on 2.4M shares in nine months ended September 30, 2026, up from $454.3M in six months ended June 30, 2026.
- SmartDose 3.5mL sale to AbbVie closed on July 1, 2026, net gain of $55.7M, SmartDose revenue removed from net sales.
- Added footnote (2) and (3) explaining confidential treatment and omitted schedules for the new Daikyo exhibits.
Changed
Everything here comes from West Pharmaceutical Services Inc's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Oct 29, 2026, from the 10-Q for Sep 2026.